Target
Cytomegalovirus - unspecified
Description
Anti-Cytomegalovirus - unspecified Antibody, Non-Fucosylated (BioBet-730ZP) is a human monoclonal IgG2 antibody against Cytomegalovirus - unspecified. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cytomegalovirus infection
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Cytomegalovirus - unspecified antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
Cytomegalovirus-unspecified
Background
Cytomegalovirus (from the Greek cyto-, "cell", and megalo-, "large") is a genus of viruses in the order Herpesvirales, in the family Herpesviridae, in the subfamily Betaherpesvirinae. Human and monkeys serve as natural hosts. There are currently eight species in this genus including the type species human herpesvirus 5. Diseases associated with HHV-5 include mononucleosis, and pneumonias. It is typically abbreviated as CMV.
Alternative Names
CMV; Cytomegalovirus-unspecified
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
TCN-202, a broadly protective, fully human monoclonal antibody in development for the treatment of human cytomegalovirus (CMV) infection. TCN-202 is directed against a universal target within CMV variations, and this Phase 1 study is a significant step in bringing an important new treatment to patients with CMV infection.
Antibody Indication
Cytomegalovirus infection
